Rho (D) Immune Globulin

Introduction Overview

Generic Name

RHo (D) immune globulin

Brand Name

WinRho SDF

Dosage Form

Sterilized solution for intramuscular or intravenous injection

Drug Class

Immune globulins

Pharmacokinetics

Absorption:
RHo (D) immune globulin is administered via intramuscular (IM) or intravenous (IV) routes, with absorption kinetics varying by route. When given intramuscularly, the immunoglobulin enters the systemic circulation gradually through local capillary absorption, usually detectable within hours post-injection. Intravenous administration leads to immediate systemic availability, ensuring rapid immunomodulatory effects useful in acute settings such as immune thrombocytopenic purpura (ITP). The absorption phase can be influenced by injection site vascularity and muscle mass.

Distribution:
Once in the bloodstream, RHo (D) immune globulin disperses primarily within the vascular and interstitial spaces due to its large molecular weight (~150 kDa IgG antibodies). Due to its size, it does not readily cross the placental barrier; however, a small fraction may pass to the fetus when administered to pregnant women to prevent hemolytic disease of the newborn. The volume of distribution approximates plasma volume, with minimal extravascular penetration. Binding to cognate Rh(D) antigen on erythrocytes is an important aspect of its distribution and mechanism.

Metabolism:
As a protein-based therapeutic, RHo (D) immune globulin undergoes catabolism by reticuloendothelial system cells, particularly within the liver and spleen. The IgG antibodies are degraded to amino acids via lysosomal pathways after binding and clearance of Rh(D)-positive red blood cells. This metabolic degradation does not involve cytochrome P450 enzymes or hepatic microsomal pathways, minimizing drug interactions.

Elimination:
Elimination consists primarily of reticuloendothelial clearance of immune complexes formed between administered antibodies and Rh(D)-positive erythrocytes. Free IgG antibodies are catabolized by Fc receptor-mediated uptake and proteolysis, with a typical half-life of approximately 21 to 28 days. Renal excretion of intact immunoglobulin molecules is negligible due to size. Factors influencing elimination include immune status, presence of target antigens, and patient physiological conditions such as renal or hepatic impairment.

Dosage Forms

Available Dosage Forms:
WinRho SDF is supplied as a sterile solution formulated from human plasma, intended for injection. The product is available in pre-filled syringes for intramuscular or intravenous administration; specific vial or syringe volumes and concentrations are product-dependent and should be verified with the prescribing information or manufacturer details.

Dosages for Adults and Adolescents:
For Rh immunoprophylaxis, dosing is typically calculated based on the volume of fetomaternal hemorrhage or the clinical scenario, such as 300 mcg intramuscularly at 28 weeks gestation and within 72 hours postpartum in Rh-negative mothers; dose adjustments are made accordingly. For treatment of immune thrombocytopenic purpura (ITP), doses range approximately from 50 mcg/kg to 75 mcg/kg and are administered intravenously to achieve immunomodulatory effects; dosing frequency and duration depend on clinical response.

Specific Patient Populations:
Pregnant women receive prophylactic dosing to prevent Rh isoimmunization as per obstetrical guidelines. Patients with immune thrombocytopenic purpura are dosed cautiously, considering comorbidities such as anemia or cardiac disease. The elderly and those with renal or hepatic impairment should be monitored closely, although dosage adjustments are not routinely specified but guided by clinical response and tolerability. Pediatric dosing is generally weight-based and carefully determined in specialized settings.

Mechanism Of Action

WinRho SDF contains RHo (D) immune globulin, which consists primarily of IgG antibodies targeting the Rh(D) antigen found on red blood cells (RBCs). When administered to an Rh-negative individual exposed to Rh-positive erythrocytes, these antibodies bind specifically to the Rh(D) antigen on the surface of foreign RBCs. This binding promotes clearance of these cells by the reticuloendothelial system, particularly via splenic macrophages, reducing the amount of antigenic stimulus that would otherwise provoke an endogenous immune response.

At a molecular level, the Fc region of the IgG antibodies interacts with Fc gamma receptors on phagocytic cells, facilitating opsonization and phagocytosis of Rh(D)-positive erythrocytes. This rapid removal prevents sensitization and subsequent alloimmunization, crucial in preventing hemolytic disease of the fetus and newborn (HDFN). This immune suppression mechanism capitalizes on antigen masking and immune complex formation, leading to immune tolerance.

In the treatment of immune thrombocytopenic purpura (ITP), WinRho SDF is believed to mediate immunomodulation by saturating Fc receptors on mononuclear phagocytes, thereby preventing the destruction of antibody-coated platelets. This Fc receptor blockade reduces the clearance of platelets, increasing their circulating levels. Additionally, the immune globulin may modulate the idiotype network and cytokine profiles, contributing to therapeutic efficacy.

Comparatively, other immune globulins like intravenous immunoglobulin (IVIG) also utilize Fc-mediated mechanisms but encompass polyclonal antibodies without specificity for Rh(D). WinRho SDF’s targeted action provides a unique ability to prevent Rh alloimmunization and treat ITP in Rh-positive individuals. Clinical trials and observational studies support its safety and efficacy profile when administered according to guidelines.

Pharmacological Actions

Passive immunization by providing anti-Rh(D) IgG antibodies.
Binding and removal of Rh(D)-positive erythrocytes to prevent alloimmunization.
Immunomodulation in immune thrombocytopenic purpura by Fc receptor blockade.
Reduction of maternal sensitization to fetal red blood cells during pregnancy.
Opsonization and clearance of incompatible red blood cells in transfusion reactions.
Inhibition of antibody production against Rh(D) antigen.
Modulation of idiotype-anti-idiotype network affecting immune regulation.
Anti-inflammatory effects through immune complex formation and clearance.

Therapeutic Or Clinical Uses

Prevention of Rh isoimmunization in Rh-negative individuals exposed to Rh-positive blood.
Prophylaxis against hemolytic disease of the fetus and newborn (HDFN).
Treatment of immune thrombocytopenic purpura (ITP) in Rh-positive patients.
Post-exposure prophylaxis following Rh-incompatible blood transfusions.
Used during pregnancy and postpartum to prevent sensitization to Rh-positive fetal erythrocytes.
Management of delayed hemolytic transfusion reactions caused by anti-Rh antibodies.
Adjunct therapy to reduce need for invasive interventions in alloimmunized pregnancies.
Preventing Rh sensitization in women of childbearing age after miscarriages or amniocentesis.
May be used experimentally in certain autoimmune hematologic disorders involving Rh antigens.

Side Or Adverse Effects

Allergic reactions including rash, hives, and anaphylaxis in rare cases.
Fever, chills, and flu-like symptoms post-injection.
Back pain and unusual weakness, potentially indicative of hemolysis.
Red or pink discoloration of urine due to hemoglobinuria.
Signs of hemolytic anemia such as pallor and jaundice.
Rapid breathing, tachycardia, and confusion associated with severe hemolytic events.
Potential kidney failure presenting as decreased urine output and swelling.
Thrombotic events including blood clots with neurological or respiratory symptoms.
Headache, dizziness, drowsiness, and fatigue following administration.
Nausea, vomiting, diarrhea, and abdominal pain as gastrointestinal adverse events.
Joint and muscle pain due to immune or inflammatory responses.
Flushing, increased sweating, mild itching, or injection site pain or tenderness.
Transient lymphadenopathy and local inflammatory reactions.
Risk of transmission of infectious agents despite thorough plasma screening.
Laboratory interferences, including false glucose readings.

Precautions

Avoid use in patients with IgA deficiency with anti-IgA antibodies due to risk of anaphylaxis.
Screen for hemolytic anemia prior to administration to minimize risk of exacerbation.
Use cautiously in patients with history of anemia or bleeding disorders.
Monitor renal function and urine output closely, particularly in patients with kidney disease.
Assess cardiovascular status in patients with coronary artery disease prior to use.
Inform patients about the potential for serious hypersensitivity reactions.
Avoid administration of live vaccines for at least 3 months post-treatment to ensure vaccine efficacy.
Multiple pregnancy exposures require careful documentation and timing of doses.
Consider potential for laboratory test interference affecting glucose monitoring.
Use only when clinically indicated due to risk of thrombosis and hemolysis.
Closely follow blood test parameters to monitor efficacy and adverse events.
Pregnancy and breastfeeding considered relatively safe; monitor fetal and infant outcomes.
Be aware of the risk of transmission of infectious agents from plasma-derived products.
Consider alternative therapies in patients with severe reactions or contraindications.
Maintain allergy history and be prepared to manage anaphylactic reactions.

Warnings

Contraindicated in patients with IgA deficiency and antibodies to IgA due to risk of severe allergic reaction.
Can cause life-threatening hemolysis leading to anemia, acute kidney injury, or shock.
Monitor patients closely for signs of hemolytic reactions including back pain, dark urine, and fatigue.
Risk of serious thrombotic events such as stroke, myocardial infarction, or pulmonary embolism.
Avoid use in patients with preexisting hemolytic anemia unless benefits outweigh risks.
Immediate medical attention required if symptoms of kidney failure or blood clots occur post-administration.
Administer only by qualified personnel in a monitored setting with resuscitation facilities available.
Potential interference with live attenuated vaccines reducing immunogenicity, hence vaccination timing is critical.
Rare but possible transmission of infectious agents despite donor screening and inactivation procedures.
Use with caution in patients with cardiovascular diseases or at increased thromboembolic risk.
Hemolytic reactions may be delayed and require follow-up for several hours post-dose.
Patients should be advised to seek emergent care if experiencing neurological or respiratory symptoms after injection.
Monitor vital signs frequently during and after infusion to detect early signs of adverse reaction.
Inform patients about the importance of reporting any new symptoms immediately.
Do not administer to individuals with a history of severe reactions to blood products unless absolutely necessary.

Contraindication

Known hypersensitivity or allergic reaction to RHo (D) immune globulin or any of its components.
Individuals with immunoglobulin A (IgA) deficiency with documented antibodies to IgA.
Patients with active hemolytic anemia or significant anemia related to immune globulin administration.
History of anaphylactic reaction to previous doses of immune globulin preparations.
Use is contraindicated if there is an insufficient Rh(D)-negative status verification.
Contraindicated during administration of live vaccines until 3 months post-WinRho SDF.
Known severe allergic reactions to human plasma-derived products.
Patients with hypersensitivity to blood products or history of serum sickness.
Use cautiously or avoid in severe renal impairment or failure without close monitoring.
Contraindicated in genetic or acquired coagulation disorders where thrombotic risk is elevated, without careful risk assessment.
Use not advised in patients with uncontrolled cardiovascular instability.
Hypersensitivity to preservatives or excipients in the formulation.
Contraindicated in presence of intravascular hemolysis at the time of intended administration.
Patients with multi-organ dysfunction syndrome unless benefits surpass risk.
Avoid use in patients with known severe platelet abnormalities incompatible with immune globulin therapy.

Drug Interactions

Concomitant administration with live vaccines (e.g., MMR, varicella) may reduce vaccine effectiveness.
May interfere with serologic testing and cause false-positive or false-negative results.
Potential interaction with immunosuppressive agents altering immune globulin efficacy or safety.
Use with other blood products requires careful timing to avoid adverse reactions.
Possible interference with laboratory glucose testing leading to erroneous results.
Concurrent anticoagulant therapy requires monitoring for increased bleeding or clotting risks.
Potential alteration in response to immunomodulatory drugs used in autoimmune conditions.
Interactions with drugs that affect platelet function may influence treatment outcomes in ITP.
Possible additive adverse effects with nephrotoxic agents requiring renal function monitoring.
No significant cytochrome P450 metabolism interactions expected due to protein nature of drug.
Concurrent administration with other intravenous immune globulins may increase risk of hypersensitivity.
Potential for altered pharmacokinetics of medications cleared by reticuloendothelial system when combined.
Herbal supplements that affect immune function might modify therapeutic response.
Vitamin supplementation generally does not affect RHo (D) immune globulin but should be disclosed.
Careful assessment required when administered with therapies targeting Fc receptors or B cell modulation.

Preparations Of The Drug

Sterile solution prepared from human plasma, of high purity and filtered to reduce risk of pathogen transmission.
Available in pre-filled syringes or vials intended for either intramuscular or intravenous use, depending on clinical indication.
Manufactured under stringent quality control ensuring absence of pyrogens and sterility.
Formulated to maintain stability and activity of IgG anti-Rh(D) antibodies during storage and administration.
Prepared using validated viral inactivation and removal processes including solvent/detergent treatment and filtration.
Contains preservatives or stabilizers per manufacturer's specifications to maintain solution integrity.
Packaging designed to maintain cold chain and prevent contamination, typically stored refrigerated.
Each batch tested for potency, sterility, and absence of infectious agents prior to release.
Dosing units standardized based on micrograms of anti-Rh(D) antibodies per dose.
Single-use vials and syringes designed to minimize contamination risk and ensure dosing accuracy.
Instruction for use includes proper reconstitution (if applicable), administration, and disposal guidelines.
Preparation should only be handled by trained healthcare professionals in appropriate clinical settings.
Lot-specific documentation provided to support pharmacovigilance and traceability of plasma sources.
Provides documentation to ensure compatibility with other blood products and medication safety.
Designed to minimize immunogenicity against non-target blood group antigens.